Session Information
Date: Tuesday, November 7, 2017
Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III
Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose:
Gastrointestinal tract (GIT) involvement in systemic sclerosis (SSc) is the most common internal organ involvement. Among the few validated patient-reported outcome measures for GI involvement are the University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and intestinal visual analogue scale (GI-VAS) The latter is a component of the Scleroderma Health Assessment Questionnaire[SHAQ]). Our aim was to evaluate the comparative responsiveness of these outcome measures when pts are treated and to evaluate the correlation between UCLA-SCTC GIT 2.0 and GI-VAS in our SSc population.
Methods:
115 SSc pts with two or more consecutive visits were enrolled in our study. Values of UCLA-SCTC GIT 2.0 and GI-VAS were completed by all patients at both visits,; any change in GI medication at the baseline visit was reported. ). UCLA-SCTC GIT2.0 includes 34 questions in 7 domains (reflux, distension, soilage, diarrhea, social function, emotional wellbeing and constipation). GI-VAS is a 100 mm VAS that asks the patient, how did GI symptoms interfere with patient function. Paired T test was used to detect the change between the two visits in both GIT 2.0 and GI-VAS. Pearson correlation was used to correlate tests at base line.
Results:
Ninety eight (85%) of SSc pts were females, Mean age 52 yrs (SD ± 12.9); median disease duration 7 (4-11), diffuse subtype 57 pts (50%), (47%), median baseline GIT 2.0 is 0.3 (0.1-0.7) and median baseline GI-VAS 0.8 (0-4.1) table 1.
Out of the 115 pts, only 41 pts needed a change of GI medication at base line visit (37.0%). A statistically significant difference was noted when comparing GIT scores before and after adding a new GI treatment (p=0.006, 95% CI= .05956 to 0.29258). On the other hand, GI-VAS did not show statistical differences between baseline visit and follow-up after adding medications (p=0.963, 95% CI =-0.937 to 0.89588).Baseline correlation between GIT2.0 (total score) and GI-VAS were (r= 0.657 ) moderate.
Conclusion:
: Both UCLA-SCTC GIT2.0 and GI -VAS reflect GIT involvement. Unlike the GI-VAS, the UCLA-SCTC GIT2.0 was responsive to treatment . These results also, shows that both tests may represent different aspects of GI involvement and might be considered separately in clinical evaluation of GI system in SSc patients. Discussion: More patients are to be included in this cohort, as the pts had low GIT scores( few symptoms ), multiple GI treatments were used and this is a retrospective evaluation of prospectively gathered data.
Table 1: Baseline characteristics of systemic sclerosis patients
|
Variable |
Mean(SD, Range), number (percentage) |
|
Age |
52 (12.9) |
|
females |
98(85%) |
|
Body mass index (BMI), mean (SD) |
24.1(5.7) |
|
Disease duration |
7 (4-11) |
|
Intestinal GI- VAS |
0.8(0-9.5) |
|
UCLA GIT 2.0 |
0.3 (0.1- 2.15) |
|
Interstitial lung disease |
66 (57%) |
|
FVC |
89% (23.2) |
|
Pulmonary artery hypertension |
19 (16%) |
To cite this abstract in AMA style:
Suliman YA, Kafaja S, Alemam M, Shaweesh Y, Tavakoli K, Furst DE. Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/responsiveness-of-university-of-california-los-angeles-scleroderma-clinical-trial-consortium-git2-0-and-intestinal-visual-analogue-scale-to-change-in-systemic-sclerosis-patients/. Accessed .« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/responsiveness-of-university-of-california-los-angeles-scleroderma-clinical-trial-consortium-git2-0-and-intestinal-visual-analogue-scale-to-change-in-systemic-sclerosis-patients/